DOCSLIB.ORG

Ep 2455362 A1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ep 2455362 A1 (19) & (11) EP 2 455 362 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 23.05.2012 Bulletin 2012/21 C07C 233/65 (2006.01) A61K 31/165 (2006.01) C07D 221/12 (2006.01) A61K 31/55 (2006.01) (2006.01) (2006.01) (21) Application number: 12150818.8 A61K 31/445 A61K 31/40 A61K 31/138 (2006.01) (22) Date of filing: 28.11.2006 (84) Designated Contracting States: • Hong, Seoung-Soo AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Collierville, Tennessee 38017 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Miller, Duane, D. SK TR Germantown, Tennessee 38139 (US) Designated Extension States: • Mohler, Michael, L. AL BA HR MK RS Memphis, Tennessee 38134 (US) • Narayanan, Ramesh (30) Priority: 28.11.2005 US 73989805 P Cordova, Tennessee 38018 (US) • Wu, Zhongzhi (62) Document number(s) of the earlier application(s) in Memphis, Tennessee 38107 (US) accordance with Art. 76 EPC: 06838432.0 / 1 954 670 (74) Representative: Lord, Hilton David Marks & Clerk LLP (71) Applicant: GTX, Inc. 90 Long Acre Memphis, TN 38163 (US) London WC2E 9RA (GB) (72) Inventors: • Dalton, James, T. Remarks: Upper Arlington, Ohio 43220 (US) This application was filed on 11-01-2012 as a • Barrett, Christina divisional application to the application mentioned Oakland, Tennessee 38060 (US) under INID code 62. • He, Yali Germantown, Tennessee 38139 (US) (54) Nuclear receptor binding agents (57) The present invention relates to a novel class of as prostrate and breast cancer, osteoporosis, hormone- selective estrogen receptor modulators (SERMs). The related diseases, hot flashes or vasomotor symptoms, SERM compounds are applicable for use in the preven- neurological disorders, cardiovascular disease and tion and/or treatment of a variety of diseases and condi- obesity. tions including prevention and treatment of cancers such EP 2 455 362 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 455 362 A1 Description FIELD OF THE INVENTION 5 [0001] The present invention relates to a novel class of nuclear receptor binding agents (NRBAs). The NRBA com- pounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including, inter alia, prevention and treatment of hormone-related diseases, cancers, inflammation, osteoporosis, peripheral vascular disease, neurological disorders, ocular disorders, cardiovascular disease and obesity. 10 BACKGROUND OF THE INVENTION [0002] The nuclear hormone receptor superfamily of ligand activated transcription factors is present in various tissues, and responsible for a multitude of effects in these tissues. [0003] The nuclear receptor (NR) superfamily presently comprises approximately 48 different proteins, most of which 15 are believed to function as ligand activated transcription factors, exerting widely different biological responses by regu- lating gene expression. Members of this family include receptors for endogenous small, lipophilic molecules, such as steroid hormones, retinoids, vitamin D and thyroid hormone. [0004] The nuclear receptor (NR) superfamily includes the steroid nuclear receptor subfamily, such as the mineralo- corticoid receptor (MR) (or aldosterone receptor), the estrogen receptors (ER), ER alpha and ER beta, the androgen 20 receptor (AR), the progesterone receptors (PR), glucocorticoid receptors (GR) and others. Also closely related in structure are the estrogen related receptors (ERRs) ERR-alpha, ERR-beta and ERR-gamma. The steroid nuclear receptors perform important functions in the body some of which are related to the transcriptional homeostasis of electrolyte and water balance, growth, development and wound healing, fertility, stress responses, immunological function, and cognitive functioning. The effects may be mediated by cytosolic or nuclear events. The effects may be mediated by cytosolic or 25 nuclear events. Accordingly, compounds that modulate (i.e. antagonize, agonize, partially antagonize, partially agonize) the activity of steroid nuclear receptors are important pharmaceutical agents that have specific utility in a number of methods, as well as for the treatment and prevention of a wide range of diseases and disorders modulated by the activity of steroid nuclear receptors. [0005] Members of the steroid nuclear receptor sub-family exhibit significant homology to each other and possess 30 closely related DNA and ligand binding domains. [0006] Given the close similarity in ligand binding domains of the steroid nuclear receptors, it is not surprising that many naturally occurring and synthetic molecules possess the ability to modulate the activity of more than one steroid nuclear receptor. 35 SUMMARY OF THE PRESENT INVENTION [0007] In one embodiment, this invention provides a nuclear receptor binding agent (NRBA), which in one embodiment is a selective estrogen receptor modulator (SERM) compound or its prodrug, analog, isomer, metabolite, derivative, pharmaceutically acceptable salt, pharmaceutical product, polymorph, crystal, impurity, N-oxide, ester, hydrate or any 40 combination thereof, represented by the structure of formula I: 45 50 wherein 55 X is CO, CS, (CH2)q, branched alkyl, branched alkyl with haloalkyl side chain, haloalkyl, C(O)(CH2)q, SO, or SO2; R1, R2 and R 3 are independently, hydrogen, halogen, aldehyde, COOH, CHNOH, CH=CHCO 2H, hydroxyalkyl, hydroxyl, alkoxy, cyano, nitro, 3CF, NH2, NHR, NHCOR, N(R)2, sulfonamide, SO2R, alkyl, aryl, protected hydroxyl, OCH2CH2NR4R5, Z-Alk-Q, Z-Alk-NR4R5, Z-Alk-heterorycle or OCH2CH2-heterocycle in which the heterocycle is a 3-7 2 EP 2 455 362 A1 membered substituted or unsubstituted heterocyclic ring, optionally aromatic, or R 1 R2 or R 3 together with the benzene ring to which the R- group is attached comprises a fused ring system represented by structure A 5 10 wherein; R6 and R7 are independently R1, R2 or R3; R is alkyl, hydrogen, haloalkyl, dihaloalkyl, trihaloalkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl, CN, 15 NO2, or OH; R4 and R5 are independently hydrogen, phenyl, an alkyl group of 1 to 6 carbon atoms, a 3 to 7 membered cycloalkyl, a 3 to 7 membered heterocycloalkyl, or a 3 to 7 membered heteroaryl group; Z is O, NH, CH2 or 20 25 Q is SO3H, CO2H, CO2R, NO2, tetrazole, SO2NH2 or SO2NHR; j, k, l are independently 1-5; q is 1-5; Alk is linear alkyl of 1-7 carbons, branched alkyl of 1-7 carbons, or cyclic alkyl of 3-8 carbons; and if X is (CH2)q, CO or C(O)(CH2)q, and R2 is OCH2CH2NR4R5, or OCH2CH2-heterocycle when k is 1, then R1 or R3 is 30 not hydrogen, lower alkyl (1-4 carbons), lower alkoxy (1-4 carbons), halogen, nitro or amino; if X is (CH2)q, CO or C(O)(CH2)q, aud R3 is OCH2CH2NR4R5, or OCH2CH2-heterocycle when 1 is one, then R1 or R2 is not hydrogen, lower alkyl (1-4 carbons), lower alkoxy (1-4 carbons), halogen, nitro or amino. [0008] In one embodiment, this invention provides a NRBA, which in one embodiment is a SERM compound or its prodrug, analog, isomer, metabolite, derivative, pharmaceutically acceptable salt, pharmaceutical product, polymorph, 35 crystal, impurity, N-oxide, ester, hydrate or any combination thereof, represented by the structure of formula I: 40 45 wherein 50 X is CS, branched alkyl, branched alkyl with haloalkyl side chain, haloalkyl, SO, or SO2; R1, R2 and R 3 are independently, hydrogen, halogen, aldehyde, COOH, CHNOH, CH=CHCO 2H, hydroxyalkyl, hydroxyl, alkoxy, cyano, nitro, 3CF, NH2, NHR, NHCOR, N(R)2, sulfonamide, SO2R, alkyl, aryl, protected hydroxyl, OCH2CH2NR4R5, Z(CH2)qQ, Z-Alk-NR4R5, Z-Alk-heterocycle or OCH2CH2-heterocycle in which the heterocycle is a 3-7 membered substituted or unsubstituted heterocyclic ring, optionally aromatic; 55 or R 1, R 2 or R 3 together with the benzene ring to which the R- group is attached comprises a fused ring system represented by structure A 3 EP 2 455 362 A1 5 wherein R6 or R7 are independently R1, R2 or R3; R is alkyl, hydrogen, haloalkyl, dihaloalkyl, trihaloalkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl, CN, 10 NO2, or OH; R4 and R5 are independently hydrogen, phenyl, an alkyl group of 1 to 6 carbon atoms, a 3 to 7 membered cycloalkyl, a 3 to 7 membered heterocycloalkyl, or a 3 to 7 membered heteroaryl group; Z is O, NH, CH2, or 15 Q is SO3H, CO2H, CO2R, NO2, tetrazole, SO2NH2, or SO2NHR; 20 j, k, 1 are independently 1-5; q is 1-5; Alk is linear alkyl of 1-7 carbons, branched alkyl of 1-7 carbons or cyclic alkyl of 3-8 carbons. [0009] In one embodiment this invention provides a NRBA, which in one embodiment is a SERM compound or its prodrug, analog, isomer, metabolite, derivative, Pharmaceutically acceptable salt, pharmaceutical product, polymorph, 25 crystal, impurity, N-oxide, ester, hydrate or any combination thereof, represented by the structure of formula II: 30 35 40 X is CO, CS, (CH2)q, branched alkyl, branched alkyl with haloalkyl side chain, haloalkyl, C(O)(CH2)q, SO, or SO2; R1, R2 and R 3 are independently, hydrogen, halogen, aldehyde, COOH, CHNOH, CH=CHCO 2H, hydroxyalkyl, hydroxyl, alkoxy, cyano, nitro, 3CF, NH2, NHR, NHCOR, N(R)2, sulfonamide, SO2R, alkyl, aryl, protected hydroxyl, OCH2CH2NR4R5, Z-Alk-Q, Z-Alk-NR4R5, Z-Alk-heterocycle or OCH2CH2-heterocycle in which the heterocycle is a 3-7 membered substituted or unsubstituted heterocyclic ring, optionally aromatic, 45 or R 1, R 2 or R 3 together with the benzene ring to which the R- group is attached comprises a fused ring system represented by structure A 50 55 wherein R6 and R7 are independently R1, R2 or R3; R is alkyl, hydrogen, haloalkyl, dihaloalkyl, trihaloalkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl,
Load more

Recommended publications
  • Ep 2732820 A1
    (19) TZZ ¥ Z_T (11) EP 2 732 820 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 21.05.2014 Bulletin 2014/21 A61K 31/675 (2006.01) A61K 31/66 (2006.01) A61K 31/47 (2006.01) (21) Application number: 14154215.9 (22) Date of filing: 14.04.2008 (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • Dalton, James T. HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT Lakeland, TN Tennessee 38002 (US) RO SE SI SK TR • Miller, Duane D. Collierville, TN Tennessee 38017-8799 (US) (30) Priority: 13.04.2007 US 785064 (74) Representative: Pearl Cohen Zedek Latzer Baratz (62) Document number(s) of the earlier application(s) in UK LLP accordance with Art. 76 EPC: 15 Old Bailey 08742872.8 / 2 136 815 London EC4M 7EF (GB) (71) Applicant: University of Tennessee Research Remarks: Foundation This application was filed on 06-02-2014 as a Knoxville, TN 37996-4122 (US) divisional application to the application mentioned under INID code 62. (54) Selective androgen receptor modulators for treating cancer (57) A composition comprising a compound of for- or its isomer, pharmaceutically acceptable salt, pharma- mula III characterized by the structure: ceutical product, hydrate, or N-oxide, and a chemother- apeutic agent. The chemotherapeutic agent may com- prise a taxane and a platinum compound, such as car- boplatin and docetaxel. The composition is for use in treating cancer in a subject. EP 2 732 820 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 732 820 A1 Description FIELD OF THE INVENTION 5 [0001] This invention provides SARM compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter-alia, diabetes and associated diseases, such as, for example, chronic kidney disease, neph- ropathy, neuropathy and retinopathy; diabetes, insulin resistance, cachexia, cardiovascular disease and associated conditions such as, atherosclerosis, cerebrovascular disease, and others.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,853,266 B2 Dalton Et Al
    USOO8853266B2 (12) United States Patent (10) Patent No.: US 8,853,266 B2 Dalton et al. (45) Date of Patent: *Oct. 7, 2014 (54) SELECTIVE ANDROGEN RECEPTOR 3,875,229 A 4, 1975 Gold MODULATORS FOR TREATING DABETES 4,036.979 A 7, 1977 Asato 4,139,638 A 2f1979 Neri et al. 4,191,775 A 3, 1980 Glen (75) Inventors: James T. Dalton, Upper Arlington, OH 4,239,776 A 12/1980 Glen et al. (US): Duane D. Miller, Germantown, 4,282,218 A 8, 1981 Glen et al. TN (US) 4,386,080 A 5/1983 Crossley et al. 4411,890 A 10/1983 Momany et al. (73) Assignee: University of Tennessee Research 4,465,507 A 8/1984 Konno et al. F dati Kn ille, TN (US) 4,636,505 A 1/1987 Tucker Oundation, Knoxv1lle, 4,880,839 A 1 1/1989 Tucker 4,977,288 A 12/1990 Kassis et al. (*) Notice: Subject to any disclaimer, the term of this 5,162,504 A 11/1992 Horoszewicz patent is extended or adjusted under 35 5,179,080 A 1/1993 Rothkopfet al. U.S.C. 154(b) by 992 days. 5,441,868 A 8, 1995 Lin et al. 5,547.933 A 8, 1996 Lin et al. This patent is Subject to a terminal dis- 5,609,849 A 3/1997 Kung claimer. 5,612,359 A 3/1997 Murugesan et al. 5,618,698 A 4/1997 Lin et al. 5,621,080 A 4/1997 Lin et al. (21) Appl. No.: 11/785,064 5,656,651 A 8/1997 Sovak et al.
    [Show full text]
  • Aromatase Inhibitors As Potential Cancer Chemopreventives
    V Vol. 7, 65-78, Januar’, 1998 Cancer Epidemiology, Biomarkers & Prevention 65 Review Aromatase Inhibitors as Potential Cancer Chemopreventives Gary J. Kelloff,t Ronald A. Lubet, Ronald Lieberman, local estrogen production may be an alternative strategy, Karen Eisenhauer, Vernon E. Steele, James A. Crowell, as suggested by the discovery of a unique transcriptional Ernest T. Hawk, Charles W. Boone, and promoter of aromatase gene expression, 1.4, in breast Caroline C. Sigman adipose tissue. The development of drugs that target this Chemoprevention Branch, Division of Cancer Prevention and Control, promoter region may be possible. National Cancer Institute, Bethesda, Maryland 20852 1G. J. K., R. A. L., R. L.. V. E. S., J. A. C., E. T. H., C. W. B.l; and CCS Associates, Mountain View, Califomia 94043 1K. E., C. C. S.] Strategies in Development of Cancer Chemopreventive Agents This paper is the third in a series on strategies used by the Abstract Chemoprevention Branch of the National Cancer Institute to Epidemiological and experimental evidence strongly develop cancer chemoprevention drugs ( 1-3). One chemopre- supports a role for estrogens in the development and ventive strategy for hormone-dependent cancers is to interfere growth of breast tumors. A role for estrogen in prostate with the hormones that stimulate cellular proliferation in these neoplasia has also been postulated. Therefore, one tumors. Among the most important of these targets for inter- chemopreventive strategy for breast and prostate cancers vention are estrogen-responsive tumors. Estrogen production is to decrease estrogen production. This can be can be decreased by inhibiting aromatase, the enzyme cata- accomplished by inhibiting aromatase, the enzyme that lyzing the final, rate-limiting step in estrogen biosynthesis.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Reproductive Health Guideline Appendix 3 – Search Strategies
    SUPPLEMENTARY APPENDIX 3: Search Strategies 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases All searches initially run on 11/8/2017 and updated on 5/8/2018. Searches run from database inception to 5/8/2018. PUBMED Syntax Guide for PubMed [MeSH] = Medical Subject Heading [Text Word] = Includes all words and numbers in the title, abstract, other abstract, MeSH terms, MeSH Subheadings, Publication Types, Substance Names, Personal Name as Subject, Corporate Author, Secondary Source, Comment/Correction Notes, and Other Terms - typically non-MeSH subject terms (keywords)…assigned by an organization other than NLM [MeSH subheading] = a Medical Subject [Title/Abstract] = Includes words in the title Heading subheading, e.g.
    [Show full text]
  • (10) Patent No.: US 8080682 B2
    US008080682B2 (12) United States Patent (10) Patent No.: US 8,080,682 B2 Dalton et al. (45) Date of Patent: Dec. 20, 2011 (54) SUBSTITUTEDACYLANILIDES AND E. 9:2: 3. 3. METHODS OF USE THEREOF GB 1360001 3, 1970 JP 52-128329 1Of 1977 (75) Inventors: James T. Dalton, Lakeland, TN (US); JP 54-63047 12, 1980 Duane D. Miller, Germantown, TN (US) WO WO95/1977O 7, 1995 WO WO9805962 2, 1998 (73) Assignee: University of Tennessee Research W W g 3. 3. 2. Foundation, Knoxville, TN (US) WO WOO127622 4/2001 - WO WOO128990 4/2001 (*) Notice: Subject to any disclaimer, the term of this WO WOO1 34.563 5, 2001 patent is extended or adjusted under 35 WO WOO2 OO617 1, 2002 U.S.C. 154(b) by 647 days. WO WO O2, 16310 2, 2002 WO WOO3 O11302 2, 2003 WO WO 03/049675 6, 2003 (21) Appl. No.: 11/892,595 WO WOO3,065992 8, 2003 WO WOO3,O74471 9, 2003 (22) Filed: Aug. 24, 2007 WO WO 2004/064747 8, 2004 WO WO 2005/0372O1 4/2005 (65) Prior Publication Data WO WO 2005/120483 12/2005 WO WO 2007/027582 3, 2007 US 2008/OO76829 A1 Mar. 27, 2008 OTHER PUBLICATIONS Related U.S. Application Data Byrnet al. Solid-State Chemistry of Drugs, 2d, Chapter 11 Hydrates (60) Provisional application No. 60/839,665, filed on Aug. and Solvates, 233-247.* 24, 2006, provisional application No. 60/907,749, Morissette et al. Adv. Drug Delivery Rev. 2004, 56, 275-300.* filed on Apr. 16, 2007.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0103141 A1 Mckearn Et Al
    US 2002O103141A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0103141 A1 McKearn et al. (43) Pub. Date: Aug. 1, 2002 (54) ANTIANGIOGENIC COMBINATION Related U.S. Application Data THERAPY FOR THE TREATMENT OF CANCER (63) Continuation-in-part of application No. 09/470,951, filed on Dec. 22, 1999. (76)76 Inventors: John P. McKearn, Wildwood, MO (60) 23,Provisional 1998. application No. 60/113,786, filed on Dec. (US); Gary B. Gordon, Highland Park, IL (US); James Cunningham, Chicago, Publication Classification IL (US); Stephen T. Gately, Palatine, IL (US); Alane T. Koki, Beaufort, MO (51) Int. Cl." .................. A61K 31/706; A61K 31/4745; (US); Jaime L. Masferrer, Ballwin, A61K 31/473; A61K 31/407; MO (US) A61K 31/415; A61K 31/277 (52) U.S. Cl. ............................ 514/43; 514/283; 514/297; Correspondence Address: 514/410; 424/450; 514/406; Pharmacia Corporation 514/521 Corporate Patent Department P.O. BOX 5110 (57) ABSTRACT Chicago, IL 60680-9889 (US) The present invention provides combinations of a DNA (21) Appl. No.: 09/843,132 topoisomerase I inhibiting agent and a Selective COX-2 inhibiting agent for preventing, treating, and/or reducing the (22) Filed: Apr. 25, 2001 risk of developing a neoplasia disorder in a mammal. US 2002/0103141 A1 Aug. 1, 2002 ANTIANGIOGENIC COMBINATION THERAPY Chemotherapy involves the disruption of cell replication or FOR THE TREATMENT OF CANCER cell metabolism. Chemotherapy is used most often in the 0001. This application is a continuation-in-part of U.S. treatment of breast, lung, and testicular cancer.
    [Show full text]
  • Uva-DARE (Digital Academic Repository)
    UvA-DARE (Digital Academic Repository) Improving treatment strategies in ovarian cancer: Towards individualized patient care van Meurs, H.S. Publication date 2015 Document Version Final published version Link to publication Citation for published version (APA): van Meurs, H. S. (2015). Improving treatment strategies in ovarian cancer: Towards individualized patient care. General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl) Download date:28 Sep 2021 Chapter 5 Hormone therapy in ovarian granulosa cell tumors: A systematic review H.S. van Meurs L.R.C.W. van Lonkhuijzen J. Limpens J. van der Velden M.R. Buist Gynecologic Oncology. 2014 Jul; 134(1):196-205 76 Chapter 5 ABSTRACT Objective This systematic review assessed the effectiveness of hormone therapy (HT) in patients with a granulosa cell tumor (GCT) of the ovary.
    [Show full text]
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
    Molecules 2016, 21, 75; doi:10.3390/molecules21010075 S1 of S110 Supplementary Materials: Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs Fei Mao 1, Wei Ni 1, Xiang Xu 1, Hui Wang 1, Jing Wang 1, Min Ji 1 and Jian Li * Table S1. Common names, indications, CAS Registry Numbers and molecular formulas of 6891 approved drugs. Common Name Indication CAS Number Oral Molecular Formula Abacavir Antiviral 136470-78-5 Y C14H18N6O Abafungin Antifungal 129639-79-8 C21H22N4OS Abamectin Component B1a Anthelminithic 65195-55-3 C48H72O14 Abamectin Component B1b Anthelminithic 65195-56-4 C47H70O14 Abanoquil Adrenergic 90402-40-7 C22H25N3O4 Abaperidone Antipsychotic 183849-43-6 C25H25FN2O5 Abecarnil Anxiolytic 111841-85-1 Y C24H24N2O4 Abiraterone Antineoplastic 154229-19-3 Y C24H31NO Abitesartan Antihypertensive 137882-98-5 C26H31N5O3 Ablukast Bronchodilator 96566-25-5 C28H34O8 Abunidazole Antifungal 91017-58-2 C15H19N3O4 Acadesine Cardiotonic 2627-69-2 Y C9H14N4O5 Acamprosate Alcohol Deterrant 77337-76-9 Y C5H11NO4S Acaprazine Nootropic 55485-20-6 Y C15H21Cl2N3O Acarbose Antidiabetic 56180-94-0 Y C25H43NO18 Acebrochol Steroid 514-50-1 C29H48Br2O2 Acebutolol Antihypertensive 37517-30-9 Y C18H28N2O4 Acecainide Antiarrhythmic 32795-44-1 Y C15H23N3O2 Acecarbromal Sedative 77-66-7 Y C9H15BrN2O3 Aceclidine Cholinergic 827-61-2 C9H15NO2 Aceclofenac Antiinflammatory 89796-99-6 Y C16H13Cl2NO4 Acedapsone Antibiotic 77-46-3 C16H16N2O4S Acediasulfone Sodium Antibiotic 80-03-5 C14H14N2O4S Acedoben Nootropic 556-08-1 C9H9NO3 Acefluranol Steroid
    [Show full text]
  • Precocious Puberty
    PRECOCIOUS PUBERTY DR AE AL-AGHA MBBS,DCH,CABP,MRCP Puberty Puberty (Latin pubescere, to be covered with hair) The stage between the onset of secondary sexual characteristics and the completion of physical maturity The period in which reproductive capability is attained,manifested by spermatogenesis in males and ovulation in females Puberty In girls starts 8 - 13 (mean 11) years In boys starts 9 - 14 (mean12) years In girls starts with BA = 10 year In boys starts with BA = 11year Puberty in boys Psychological / emotional changes First sign is testicular enlargement followed by pubic hair development and genital enlargement Puberty starts when the testes are 4 ml in size (measured by Orchidometer) Adult testes are 20-25 ml in size Somatic changes in boys Growth spurt is later than girls by 2 yr Increased muscle mass Decreased adipose tissue Skeletal changes (↑ BMD) 60% have transient gynaecomastia Spermatogenesis by 13.5 yr Puberty in girls Psychological / emotional changes. First sign is breast enlargement followed by adrenarche and pubarche. Pelvic U/S changes of puberty ↑ ovarian volume and follicular size ↑ uterus to cervix ratio ↑ endometrial echo Pelvic U/S changes Ovary volume prepuberty < 1.5 ml postpuberty > 3-4 ml Follicle size prepuberty < 6mm postpuberty > 6mm Uterus to cervix ratio prepuberty ≤ 1 postpuberty >1 Endometrial echo prepuberty = None postpuberty=present Skeletal changes in girls Widening of pelvis and carrying angle Major increase in BMD Increased adipose tissue with typical female distribution
    [Show full text]
  • Tepzz¥ 47 78A T
    (19) TZZ¥_ _T (11) EP 3 147 278 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 29.03.2017 Bulletin 2017/13 C07C 255/51 (2006.01) A61K 31/167 (2006.01) A61P 15/16 (2006.01) C07C 255/60 (2006.01) (21) Application number: 16194602.5 (22) Date of filing: 12.07.2007 (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • DALTON, James T. HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE Ann Arbor, MI 48103 (US) SI SK TR • MILLER, Duane D. Collierville, TN 38017 (US) (30) Priority: 12.07.2006 US 830158 P 24.08.2006 US 839665 P (74) Representative: Pearl Cohen Zedek Latzer Baratz 16.04.2007 US 907748 P UK LLP 16 Upper Woburn Place (62) Document number(s) of the earlier application(s) in London WC1H 0BS (GB) accordance with Art. 76 EPC: 07796823.8 / 2 038 252 Remarks: This application was filed on 19-10-2016 as a (71) Applicant: University of Tennessee Research divisional application to the application mentioned Foundation under INID code 62. Knoxville, TN 37996 (US) (54) COMPOUND FOR TREATING BREAST CANCER AND PROGESTIN-DEPENDENT CONDITIONS (57) This invention provides a pharmaceutical com- or its isomer, pharmaceutically acceptable salt, pharma- position comprising a compound of formula S-(I): ceutical product, crystal, N-oxide, hydrate or any combi- nation thereof, for use in treating or preventing breast cancer in a subject. EP 3 147 278 A1 Printed by Jouve, 75001 PARIS (FR) EP 3 147 278 A1 Description FIELD OF THE INVENTION 5 [0001] This invention provides substituted acylanilide compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter-alia, a muscle wasting disease and/or disorder or a bone-related disease and/or disorder BACKGROUND OF THE INVENTION 10 [0002] The nuclear hormone receptor superfamily is one of the largest classes of transcription factors and is involved in abundant physiological processes.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,110,562 B2 Dalton Et Al
    US008110562B2 (12) United States Patent (10) Patent No.: US 8,110,562 B2 Dalton et al. (45) Date of Patent: Feb. 7, 2012 (54) SELECTIVE ANDROGEN RECEPTOR (52) U.S. Cl. .......... 514/80; 514/297: 514/311:546/102; MODULATORS, ANALOGS AND 54.6/104:546/107: 546/165; 546/166 DERVATIVES THEREOF AND USES (58) Field of Classification Search ........................ None THEREOF See application file for complete search history. (75) Inventors: James T. Dalton, Upper Arlington, OH (56) References Cited (US): Duane D. Miller, Germantown, TN (US); Igor Rakov, Marion, AR (US); U.S. PATENT DOCUMENTS Casey Bohl, Columbus, OH (US); Michael L. Mohler, Memphis, TN (US) 2,684.965 A 7, 1954 Weston et al. FOREIGN PATENT DOCUMENTS (73) Assignees: University of Tennessee Research GB T984.10 7, 1958 Foundation, Knoxville, TN (US); The WO WOO3/031436 4/2003 Ohio State University Research Foundation, Columbus, OH (US) OTHER PUBLICATIONS Beadle, C.D. (2005) “1-Aryl-3,4-dihydro-1H-qwuinolin-2-one (*) Notice: Subject to any disclaimer, the term of this derivatives, nove and selective norepinephrine re-uptake inhibitors.” patent is extended or adjusted under 35 Bioorganic & medicinal Chemistry Letters, vol. 15, No. 20, 4432 U.S.C. 154(b) by 1097 days. 4437. Steinhagen et al., “A Convenient and Versatile Route to (21) Appl. No.: 11/826,987 Hydroquinolines by Inter- and Intramolecular Aza-Diels-Alder Path ways' Angew. Chem. Int. Ed. 1999, 38, No. 13/14, pp. 1928-1931; (22) Filed: Jul.19, 2007 Chemical Abstracts Accession No. 1999:470219 and CAS Registry (Under 37 CFR 1.47) File RN 243844-52-2.
    [Show full text]